Zibotentan + Dapagliflozin for Liver Cirrhosis (ZEAL Trial)

"Affirmative. Clinicaltrials.gov data indicates that this clinical trial is currently accepting applications, which were first posted on October 31st 2022 and more recently modified on November 21st 2022. The study requires participants from 8 distinct sites for a total of 140 patients."

"This medical study is seeking participants between the ages of 18 and 80, providing 76 opportunities for younger patients, and 412 potential spots for those aged 65 or above."

"After rigorous assessment, our team at Power determined the safety of Part A: Treatment Group 1 to be a 2. This Phase 2 trial has collected evidence that suggests it is safe but none supporting its efficacy."

"At the moment, 8 distinct medical centers are enrolling participants for this clinical trial. These locations are located in Charleston, Rochester and San Diego among various other cities. To reduce travelling burdens, it is suggested that you select a site closest to your residence if you plan on joining the experiment."

"This medical trial is seeking out 140 individuals, between the ages of 18 and 80 who have been diagnosed with liver cirrhosis. Furthermore, these potential participants must meet a variety of criteria such as not having taken any SGLT2 inhibitors or endothelin receptor antagonists within 30 days prior to enrolment; being on either no or a stable dose of beta blockers without major changes in dosage over the past month; verifying post-menopausal status through documentation and testing; confirmation that they are unable to bear children via hysterectomy or bilateral oophorectomy/salpingectomy (not tubal ligation); possessing Child"

"According to the trial sponsor, AstraZeneca, the primary outcome of this experiment will be Part B: HVPG response. Wherein a responder is defined as at least 20% decrease or reduction to 12 mmHg in HVPG from baseline to Week 6. The subsidiary outcomes that researchers are assessing include changes in total body water and fat mass volumes, percentage and absolute change of loop-diuretic equivalents use from baseline to Week 6., and also percentages/absolute change of HVGP from baseline until week six."

"According to clinicaltrials.gov, this experiment is actively recruiting subjects. The trial was initially published on October 31st 2022 and recently edited on November 21st 2022."